3,233 Shares of Moderna, Inc. $MRNA Bought by Pinkerton Wealth LLC

Pinkerton Wealth LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,233 shares of the company’s stock, valued at approximately $623,000.

A number of other institutional investors have also added to or reduced their stakes in MRNA. Greenleaf Trust boosted its stake in shares of Moderna by 4.5% in the 3rd quarter. Greenleaf Trust now owns 5,187 shares of the company’s stock worth $999,000 after buying an additional 223 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Moderna by 187.1% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,590 shares of the company’s stock valued at $11,475,000 after acquiring an additional 38,833 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Moderna during the third quarter valued at approximately $23,201,000. ProShare Advisors LLC lifted its holdings in Moderna by 6.1% during the third quarter. ProShare Advisors LLC now owns 74,898 shares of the company’s stock worth $14,423,000 after acquiring an additional 4,277 shares during the period. Finally, Vise Technologies Inc. lifted its holdings in Moderna by 63.0% during the third quarter. Vise Technologies Inc. now owns 8,879 shares of the company’s stock worth $1,710,000 after acquiring an additional 3,432 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $221.72 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. Moderna, Inc. has a one year low of $22.28 and a one year high of $254.48. The company has a market cap of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.16. The firm has a fifty day moving average price of $182.49 and a two-hundred day moving average price of $86.52.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million during the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter in the previous year, the company earned ($2.13) EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. Analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jamey Mock sold 34,836 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the transaction, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 197,251 shares of company stock valued at $33,875,904 over the last 90 days. Insiders own 10.80% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Morgan Stanley upped their price objective on Moderna from $89.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. CLSA raised shares of Moderna to an “outperform” rating in a report on Friday, August 28th. Loop Capital set a $135.00 price target on shares of Moderna in a research report on Wednesday, August 19th. Rothschild & Co Redburn lowered shares of Moderna from a “neutral” rating to a “sell” rating and increased their price target for the company from $40.00 to $81.00 in a research report on Thursday, September 3rd. Finally, Brookline Capital Markets restated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Six investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and a consensus target price of $107.10.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.